News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,979 Results
Type
Article (39594)
Company Profile (247)
Press Release (657138)
Multimedia
Podcasts (46)
Webinars (12)
Section
Business (204114)
Career Advice (2007)
Deals (35412)
Drug Delivery (95)
Drug Development (81022)
Employer Resources (172)
FDA (16165)
Job Trends (14848)
News (345087)
Policy (32513)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2553)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49389)
ALS (85)
Alzheimer's disease (1365)
Antibody-drug conjugate (ADC) (111)
Approvals (16165)
Artificial intelligence (237)
Autoimmune disease (19)
Automation (15)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (175)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (258)
Cancer (2063)
Cardiovascular disease (164)
Career advice (1674)
Career pathing (29)
CAR-T (143)
Cell therapy (400)
Cervical cancer (19)
Clinical research (65807)
Collaboration (781)
Compensation (498)
Complete response letters (19)
COVID-19 (2581)
CRISPR (37)
C-suite (221)
Cystic fibrosis (100)
Data (2035)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (255)
Diagnostics (6347)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (117)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (88)
Earnings (86287)
Editorial (33)
Employer branding (21)
Employer resources (146)
Events (111822)
Executive appointments (674)
FDA (17319)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (706)
Gene editing (99)
Generative AI (19)
Gene therapy (282)
GLP-1 (692)
Government (4397)
Grass and pollen (4)
Guidances (50)
Healthcare (18811)
Huntington's disease (22)
IgA nephropathy (24)
Immunology and inflammation (105)
Indications (26)
Infectious disease (2719)
Inflammatory bowel disease (132)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (90)
Interviews (311)
IPO (16493)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (35)
Layoffs (458)
Leadership (16)
Legal (7905)
Liver cancer (72)
Lung cancer (299)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (275)
MASH (62)
Medical device (13337)
Medtech (13342)
Mergers & acquisitions (19423)
Metabolic disorders (650)
Multiple sclerosis (73)
NASH (16)
Neurodegenerative disease (82)
Neuropsychiatric disorders (24)
Neuroscience (1864)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2507)
Now hiring (37)
Obesity (349)
Opinion (203)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (79)
Parkinson's disease (144)
Partnered (21)
Patents (217)
Patient recruitment (99)
Peanut (46)
People (57168)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20496)
Phase II (28974)
Phase III (21600)
Pipeline (1100)
Policy (123)
Postmarket research (2563)
Preclinical (8667)
Press Release (64)
Prostate cancer (97)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (368)
Real estate (5906)
Recruiting (65)
Regulatory (22185)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (40)
Schizophrenia (65)
Series A (123)
Series B (80)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2164)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3572)
State (2)
Stomach cancer (13)
Supply chain (62)
Tariffs (16)
The Weekly (27)
United States (21757)
Vaccines (661)
Venture capitalists (37)
Weight loss (227)
Women's health (34)
Worklife (15)
Date
Today (111)
Last 7 days (460)
Last 30 days (2413)
Last 365 days (33108)
2025 (8877)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (51)
Alaska (7)
Arizona (228)
Arkansas (13)
Asia (37738)
Australia (6174)
California (5703)
Canada (1922)
China (485)
Colorado (249)
Connecticut (262)
Delaware (132)
Europe (80969)
Florida (851)
Georgia (199)
Idaho (57)
Illinois (505)
India (24)
Indiana (296)
Iowa (9)
Japan (147)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (846)
Massachusetts (4285)
Michigan (214)
Minnesota (377)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (58)
New Hampshire (62)
New Jersey (1632)
New Mexico (28)
New York (1632)
North Carolina (931)
North Dakota (7)
Northern California (2507)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1288)
Puerto Rico (11)
Rhode Island (29)
South America (1095)
South Carolina (19)
South Dakota (1)
Southern California (2164)
Tennessee (96)
Texas (848)
Utah (170)
Virginia (135)
Washington D.C. (59)
Washington State (525)
West Virginia (3)
Wisconsin (51)
696,979 Results for "evommune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis
March 17, 2025
·
3 min read
Business
Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
June 24, 2024
·
3 min read
Business
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
Evommune, Inc. and Accutar Biotechnology Inc. today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
November 28, 2023
·
2 min read
Press Releases
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
November 1, 2024
·
3 min read
Business
Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.
March 20, 2024
·
3 min read
Drug Development
Evommune Announces Initiation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria
Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the initiation of its Phase 1 first-in-human study, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU).
January 18, 2024
·
3 min read
Press Releases
Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
September 3, 2024
·
3 min read
Business
Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan.
September 27, 2023
·
4 min read
Press Releases
Evommune Announces Positive Proof-of-Concept Clinical Trial Results for its MRGPRX2 Antagonist (EVO756)
July 16, 2024
·
3 min read
Business
Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team
Evommune, Inc. today announced the closing of an additional $7.5 million to its Series B financing from new investor Verition Fund Management, bringing the total raised in the Series B round to $57.5 million.
June 28, 2023
·
2 min read
1 of 69,698
Next
